SNNAQ — Sienna Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-Twitter, Tyson Foods, Tesla, Caterpillar, Exxon Mobil, AMD
U.S. STOCKS ON THE MOVE-Tyson Foods, Twitter, Tesla, AmEx, AT&T
Sienna Biopharma sinks after acne treatment fails two trials (updated)
U.S. STOCKS ON THE MOVE-Caterpillar, Tyson Foods, Sogou, Redhill Biopharma, Seagate
U.S. STOCKS ON THE MOVE-Caterpillar, Redhill Biopharma, Sienna Biopharma, Sogou
Sienna Biopharma sinks after acne drug fails two trials (updated)
Sienna Biopharma: Eyes record low as acne drug misses trial goals
Brief: Sienna Biopharmaceuticals Says Sna-001 In Acne Trials Did not Meet Primary, Secondary Endpoints
Sienna Biopharmaceuticals' acne drug fails two trials
Brief: Sienna Completes Maximal Use Safety Study Of SNA-120 In Patients With Itch Associated With Psoriasis
Brief: Sienna Biopharmaceuticals Signs $40 Mln Term Loan Agreement
Brief: Sebacia Announces Favorable Ruling By U.S. Court Regarding Patent Proceedings With Sienna Biopharma
Brief: Sienna Biopharmaceuticals Appoints John Smither As CFO
Brief: Sienna Biopharmaceuticals Qtrly Loss Per Share $0.56
Brief: Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125
Brief: Sienna Biopharmaceuticals posts qtrly loss per share $1.12
Brief: Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120
Brief: Sienna Biopharmaceuticals reports Q2 loss of $6.50/shr
Brief: Partner Fund reports 7.7 pct passive stake in Sienna Biopharmaceuticals